wadegarret
11 minutes ago
GERN is a solid hold for a double @ $4.50
Not saying when this will happen, but GERNs drug Rytelo for a deady anemia(low risk MDS) has only one competitor, Bristol Myers. Now Bristol just posted $425M in one quarter for their drug Reblozyl, despite it not being as effective for k